The Helmsley Charitable Trust has been a committed funder of research to find cures, and until then, better treatments for Crohn’s disease. For nearly a decade, Helmsley has supported various Crohn's & Colitis Foundation projects, including our research training awards and our flagship Microbiome & Genetics Initiatives – which have led to improving our knowledge of the pathophysiology of inflammatory bowel diseases (IBD).
Most recently, Helmsley committed $17.5 million to the development of IBD Plexus, a research and information exchange platform that enables scientists, researchers, clinicians, and patients to capture, organize, and share large amounts of data in order to accelerate research into the causes, treatments, and cures of Crohn’s and colitis. Launching this fall, IBD Plexus will influence how this research is being conducted by fostering collaboration and cooperation among members of the IBD community.
“At Helmsley, we are committed to finding cures for Crohn’s disease by funding research that will lead to improved prevention, diagnosis, treatment and management of this debilitating disease,” said Sandor Frankel, Trustee at the Helmsley Charitable Trust. “It is essential to keep patients at the center of this challenging mission, and we are grateful to have partners like the Crohn’s & Colitis Foundation who are true leaders in patient engagement.”